Company: BIAF
Filing Date: 2025-10-09
Form Type: 424B5
Source: 0001493152-25-017591
Chunk: 73

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-09
Form: 424B5
Chunk 73
---
/or impose price controls may adversely affect:

| ● | the                                                                                                                  
 demand for our diagnostic tests or therapeutic product candidates, if we or our licensors obtain regulatory approval |
| ● | the                                                                                                                  
 ability to set a price that we believe is fair for our diagnostic tests and therapeutic products;                    |
| ● | the                                                                                                                  
 ability to obtain coverage and reimbursement approval for a diagnostic test and therapeutic product;                 |
| ● | our                                                                                                                  
 ability to generate revenue and achieve or maintain profitability;                                                   |
| ● | the                                                                                                                  
 level of taxes that we are required to pay; and                                                                      |
| ● | the                                                                                                                  
 availability of capital.                                                                                             |

| 25 |

Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.

Risks Related to Ownership of Our Common Stock

We do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our Common Stock.

We do not anticipate paying cash dividends on our Common Stock in the foreseeable future. The payment of dividends on our Common Stock will depend on earnings, financial condition, and other business and economic factors affecting it at such time as our Board of Directors may consider relevant. If we do not pay dividends, our Common Stock may be less valuable because a return on your investment will occur only if our stock price appreciates.

Future sales of substantial amounts of shares of our Common Stock by existing shareholders could adversely affect the trading price of our Common Stock.

If our existing shareholders sell substantial amounts of shares of our Common Stock, the market price of our Common Stock could fall. In addition, the exercise of currently outstanding warrants or options could impact the market price of our Common Stock. Such sales by our existing stockholders might make it more difficult for us to issue new equity or equity-related securities in the future at a time and place we deem appropriate. If any existing stockholders sell a substantial amount of shares, the prevailing market price for our Common Stock could be adversely affected.

The financial and operational projections that we may make from time to time are subject to inherent risks.

The projections that are incorporated by reference herein or our management may provide from time to time (including, but not limited to, those relating to potential peak sales amounts, clinical and regulatory timelines, production and supply matters, commercial launch dates, and other financial or operational matters) reflect numerous assumptions made by management, including assumptions with respect to our specific as well as general